Lipoprotein-X disease in the setting of severe cholestatic hepatobiliary autoimmune disease

Robert E Heinl; Heather M Tennant; John C Ricketts; Claire R Rice; Cordelia B Robinson; Pratik B Sandesara; Patrick M Moriarty; Laurence Sperling

doi:10.1016/j.jacl.2016.09.016

Lipoprotein-X disease in the setting of severe cholestatic hepatobiliary autoimmune disease

J Clin Lipidol. 2017 Jan-Feb;11(1):282-286. doi: 10.1016/j.jacl.2016.09.016. Epub 2016 Oct 4.

Authors

Robert E Heinl¹, Heather M Tennant², John C Ricketts¹, Claire R Rice³, Cordelia B Robinson³, Pratik B Sandesara⁴, Patrick M Moriarty², Laurence Sperling⁵

Affiliations

¹ Department of Medicine, Emory University, Atlanta, GA, USA.
² Department of Clinical Pharmacology, University of Kansas Medical Center, Kansas City, KS, USA.
³ Division of Cardiology, Department of Medicine, Emory University, Atlanta, GA, USA.
⁴ Department of Medicine, Emory University, Atlanta, GA, USA; Division of Cardiology, Department of Medicine, Emory University, Atlanta, GA, USA.
⁵ Department of Medicine, Emory University, Atlanta, GA, USA; Division of Cardiology, Department of Medicine, Emory University, Atlanta, GA, USA. Electronic address: [email protected].

PMID: 28391896
DOI: 10.1016/j.jacl.2016.09.016

Abstract

Severe cholestatic disease and hyperlipidemia are both commonly encountered by medical professionals. This article reviews the current pathophysiological model of lipoprotein-X syndrome related to 3 cases from 2 academic medical centers in the United States.

Keywords: Apheresis; Cholestatic liver disease; Hyperlipidemia; Lipoprotein; Lipoprotein-X disease; Liver transplantation.

Publication types

Case Reports

MeSH terms

Adult
Autoimmune Diseases / complications*
Cholestasis / complications*
Cholestasis / metabolism*
Female
Humans
Lipoprotein-X / metabolism*
Liver Diseases / complications*
Male
Middle Aged

Substances

Lipoprotein-X